Vioxx in high doses causes hypertension

Nashville (Tenn.) - The evidence is growing: chronic, high-dose consumption of the arthritis pain reliever Vioxx can raise blood pressure and the risk of serious heart problems.

Yet a "substantial number" of patients continue to be prescribed high doses of the drug, according to researchers at Vanderbilt University Medical Center.

The researchers counted the number of prescriptions for non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, naproxen, Celebrex and Vioxx, given to participants over age 49 in Tennessee's Medicaid program, called TennCare.

Of 40,000 participants who had prescriptions for any NSAID as of July 1, 2001, nearly 10,000 were taking Vioxx, and more than 1,000 of them were "high-dose" Vioxx users, with 30-day supplies of 50-milligram pills. Half that amount -- 25 milligrams a day -- is the recommended dose for long-term use.

The 50-milligram dose has not been shown to be more effective than lower doses of the drug in relieving chronic pain, and it has been linked to an increased risk of heart attacks. "Such use should be discouraged," the researchers concluded in the June issue of the journal Pharmacoepidemiology and Drug Safety.

Vioxx (the brand name for rofecoxib) and Celebrex (celecoxib) are selective COX-2 inhibitors. They relieve inflammation by blocking the cyclooxygenase-2 enzyme, but they don't inhibit the related COX-1 enzyme, which protects the stomach lining. Therefore they don't irritate the stomach as much as NSAIDs that block both enzymes.

"They cause fewer ulcers," explained the study's lead author, Marie R. Griffin, M.D., MPH, professor of Preventive Medicine and Medicine. "That's a good thing in many ways, although there's a lot of people using them who are pretty low risk for GI (gastrointestinal) events." COX-2 inhibitors also cost $80 to $100 per month, compared to about $10 to $15 for a month's supply of generic naproxen.

"We think that the rationale is th

Contact: Clinton Colmenares
Vanderbilt University Medical Center

Page: 1 2 3

Related biology news :

1. PTEN and prostate cancer--the devil is in the doses
2. Research shows high doses of acetaminophen clear rapidly and consistently from bloodstream
3. UT Southwestern researchers say overdoses of acetaminophen cause most cases of acute liver failure
4. Extended-release niacin effective in low doses for diabetics, say UT Southwestern researchers
5. Low doses of radiation in nature may pose more risk
6. Gel may cut doses for some medications
7. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
8. Pollutant causes delayed flowering in plants
9. Disruption of protein-folding causes neurodegeneration, mental retardation
10. Researchers discover why mutant gene causes colon cancer
11. Analysis fingers causes of desertification

Post Your Comments:

(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., ... the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New ... treatment of severe COVID-19. Approval of this IND allows Sentien to initiate a ...
(Date:8/21/2020)... , ... August 20, 2020 , ... ... Hassan Movahhed , a Clinical Operations executive with expertise in clinical trial ... joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has ...
(Date:8/7/2020)... ... 06, 2020 , ... Alucio™, a fast-growing provider of cloud-based ... and Jessica Wong have joined the company’s leadership team as Vice President of ... heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based content management ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... BEDFORD, Mass. (PRWEB) , ... July 29, 2020 ... ... of highly reliable, solid-state radar transmitter systems that can be configured to drive ... a single controller that can drive one or two switches in a push-pull ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
Breaking Biology Technology:
Cached News: